Advanced Solid Tumors
Conditions
Brief summary
This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.
Interventions
BIOLOGICALAn anticancer medication (A01) and immune cells (IC01)
The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Sponsors
The Second People's Hospital of Yibin
Hangzhou Converd Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent form must be obtained prior to any research procedures; 2. Age: 18 Years to 70 Years; 3. The patient's biological parent or child whose age ≥18 years voluntarily donates peripheral blood (100-200 ml) for the treatment, and who signs the informed consent form independently; 4. Histologically confirmed diagnosis of solid tumors; 5. Patients who have received at least one standard treatment (surgery, chemotherapy, radiotherapy, or targeted therapy) or refuse to receive standard treatments; 6. KPS \> 60 points; 7. expected survival \> 6 months; 8. Adequate organ function defined as: ANC≥1.0×10\^9/L, PLT≥50×10\^9/L, ALB≥25g/L; 9. If a subject is a female of childbearing potential, she must have a negative urine pregnancy test result.
Exclusion criteria
1. Patients who received chemotherapy, large-field radiotherapy or participated in other studies of anti-tumor therapy within 2 weeks before enrollment; 2. Patients who have not recovered from adverse reactions related to above-mentioned procedures; 3. Patients with two types of primary solid tumors; 4. Patients with brain metastases or bone metastases; 5. Patients with poorly controlled hypertension (systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 90 mmHg), or cardiovascular and cerebrovascular diseases with clinical significance, such as cerebrovascular accident (within 6 months before signing informed consent), myocardial infarction (within 6 months before signing informed consent), unstable angina, congestive heart failure (New York Heart Association ClassⅡ or above), or severe arrhythmia which can't be controlled with drugs or have potential impact on the treatment; 6. Patients with other serious organic diseases or mental disorders; 7. Patients with systemic or active infection; 8. Patients with positive HIV test result; 9. Patients who have received an organ transplant; 10. Patients who are breastfeeding or pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The adverse events associated with infusion of the anticancer medication or the immune cells will be assessed. | Day 0 to 4 months after the end of the study | Incidence and duration of all the adverse events will be recorded. The severity of adverse events will be evaluated according to NCI-CTCAE v4.03 criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response of the treatment in patients with advanced solid tumors. | Before treatment and Day 28 to 4 months after the end of the treatment | Response Evaluation Criteria in Solid Tumors (RECIST) from the NCI will be used for assessment of radiographic response. |
Contacts
Primary ContactLin Chen, PhD
Outcome results
None listed